In Silico Screening of Multi-Domain Targeted Inhibitors for PTK6: A Method Combining Consensus Docking and Drug Repurposing

Authors

  • V. Sujitha Asst. Professor, DEPT OF Pharmacology, NARAYANA PHARMACY COLLEGE, CHINTHA REDDY PALEM, NELLORE Author
  • A. Kiranmai Asst. Professor, DEPT OF Pharmaceutical Analysis, NARAYANA PHARMACY COLLEGE, CHINTHA REDDY PALEM, NELLORE Author
  • Dr. M. GOBINATH Professor, DEPT OF Pharmaceutical Chemistry, SWATHI COLLEGE OF PHARMACY, NELLORE Author
  • SB. Krishnamoorthy Asso. Professor, DEPT OF PHARMACEUTICS, NARAYANA PHARMACY COLLEGE, CHINTHA REDDY PALEM, NELLORE Author
  • Dr.M. SREENIVASULU PRINCIPAL, NARAYANA PHARMACY COLLEGE, CHINTHA REDDY PALEM, NELLORE Author

Keywords:

PTK6, drug repurposing, consensusdocking, structure based virtual screening, in silico studies

Abstract

As a non-receptor intracellular tyrosine kinase belonging to the Src kinase family, protein tyrosine kinase 6 (PTK6) is often
referred to as breast tumour kinase (BRK).PTK6 has structural similarities with other Src kinases, including a tyrosine kinase domain
(SH1), a Src homology 2 (SH2) domain, and a Src homology 3 (SH3) domain.Although a lot of work has gone into creating PTK6
inhibitors that target the SH1 domain, which is in charge of kinase activity in a number of pathways, it has been shown that PTK6
activity cannot be successfully suppressed by only blocking the SH1 domain. The role of SH2 and SH3 domains in intramolecular and
substrate binding interactions, which are essential for PTK6 activity, has been shown by further experiments. Therefore, it becomes
essential to identify PTK6 inhibitors that target the SH2 and SH3 domains in addition to the SH1 domain. Four putative ligands that
may concurrently inhibit the tyrosine kinase domain and SH2/SH3 domains of PT6K have been effectively discovered by an
insilicostructural-based virtualscreening technique that incorporates drugre purposing and a consensus docking approach. This
discovery raises the possibility of treatment approaches including PTK6 inhibition

References

Brauer, P.M.; Tyner, A.L. Building A Better Understanding of the Intracellular Tyrosine Kinase PTK6-BRK by BRK. Biochim. Biophys. Acta2010, 1806, 66–73. [CrossRef] [PubMed]

Peng, M.; Emmadi, R.; Wang, Z.; Wiley, E.L.; Gann, P.H.; Khan, S.A.; Banerji, N.; McDonald, W.; Asztalos, S.; Pham, T.N.; et al. PTK6/BRKIsExpressedintheNormalMammaryGlandandActivatedatthePlasmaMembraneinBreastTumors. Oncotarget 2014, 5, 6038–6048. [CrossRef] [PubMed]

Ostrander,J.H.;Daniel,A.R.;Lange,C.A.Brk/PTK6SignalinginNormalandCancerCellModels.Curr.Opin.Pharm.2010,10,

Zheng,Y.;Wang,Z.;Bie,W.;Brauer,P.M.;PerezWhite,B.E.;Li,J.;Nogueira,V.;Raychaudhuri,P.;Hay,N.;Tonetti,D.A.; etal. PTK6ActivationattheMembraneRegulatesEpithelial-MesenchymalTransitioninProstateCancer. CancerRes.2013,73, 5426– 5437. [CrossRef] [PubMed]

Aubele,M.;Vidojkovic,S.;Braselmann,H.;Ritterswürden,D.;Auer,G.;Atkinson,M.J.;Tapio,S.;Höfler,H.;Rauser,S.;Bartlett, J.M. Overexpression of PTK6 (Breast Tumor Kinase) Protein—A Prognostic Factor for Long-Term Breast Cancer Survival—Is notDue to Gene Amplification.Virchows Arch. Int. J. Pathol. 2009, 455, 117–123.[CrossRef]

Alwanian,W.M.;Vlajic,K.;Bie,W.;Kajdacsy-Balla,A.;Tyner,A.L.ProteinTyrosineKinase6RegulatesActivationofSRCKinase. J.Biol.Chem.2022,298,102584.[CrossRef]

Jerin,S.;Harvey,A.J.;Lewis,A.TherapeuticPotentialofProteinTyrosineKinase6inColorectalCancer.Cancers2023,15,3703.[CrossRef]

Liu,C.;Pan,Z.;Chen,Q.PharmacologicalTargetingPTK6InhibitstheJAK2/STAT3SustainedStemnessandReversesChemore-sistance of Colorectal Cancer.J. Exp. Clin. Cancer Res. 2021, 40, 297.[CrossRef]

Park,S.H.;Ito,K.;Olcott,W.;Katsyv,I.;Halstead-Nussloch,G.;Irie,H.Y.PTK6InhibitionPromotesApoptosisofLapatinib- ResistantHer2(+)BreastCancerCellsbyInducingBim. BreastCancerRes. BCR2015,17,86. [CrossRef]

Qiu,L.;Levine,K.;Gajiwala,K.S.;Cronin,C.N.;Nagata,A.;Johnson,E.;Kraus,M.;Tatlock,J.;Kania,R.;Foley,T.;etal.Small Molecule InhibitorsReveal PTK6Kinase isnot anOncogenic Driverin BreastCancers.PLoS ONE 2018,13,e0198374.[CrossRef]

Mathur,P.S.;Gierut,J.J.;Guzman,G.;Xie,H.;Xicola,R.M.;Llor,X.;Chastkofsky,M.I.;Perekatt,A.O.;Tyner,A.L. Kinase- Dependentand-IndependentRolesforPTK6inColonCancer.Mol.Cancer Res.MCR 2016,14,563–573.[CrossRef][PubMed]

Kim,H.I.;Lee,S.T.AnIntramolecularInteractionBetweenSH2-KinaseLinkerandKinaseDomainisEssentialfortheCatalyticActivity of Protein-Tyrosine Kinase-6. J. Biol. Chem. 2005, 280, 28973–28980. [CrossRef] [PubMed]

Kim,H.I.;Jung,J.;Lee,E.S.;Kim,Y.C.;Lee,W.;Lee,S.T.MolecularDissectionoftheInteractionBetweentheSH3Domainandthe SH2- KinaseLinkerRegioninPTK6. Biochem.Biophys.Res.Commun.2007,362,829–834. [CrossRef][PubMed]

Dwyer,A.R.;Kerkvliet,C.P.;Krutilina,R.I.;Playa,H.C.;Parke,D.N.;Thomas,W.A.;Smeester,B.A.;Moriarity,B.S.;Seagroves,T.N.; and Aryl Hydrocarbon Receptor (AhR) Signaling. Mol. CancerRes. MCR2021, 19, 329–345. [CrossRef] [PubMed]

Qiu,H.;Miller,W.T.RoleoftheBrkSH3DomaininSubstrateRecognition.Oncogene2004,23,2216–2223.[CrossRef][PubMed]

Pushpakom,S.;Iorio,F.;Eyers,P.A.;Escott,K.J.;Hopper,S.;Wells,A.;Doig,A.;Guilliams,T.;Latimer,J.;McNamee,C.;etal. DrugRepurposing: Progress,ChallengesandRecommendations. Nat.Rev.DrugDiscov.2019,18,41–58. [CrossRef][PubMed]

Parvathaneni, V.;Kulkarni, N.S.;Muth, A.;Gupta, V. Drug Repurposing:A Promising Tool to Accelerate the Drug DiscoveryProcess.DrugDiscov.Today2019,24,2076–2085.[CrossRef][PubMed]

Gonzalez-Fierro,A.;Dueñas-González,A.DrugRepurposingforCancerTherapy,EasierSaidThanDone.Semin.CancerBiol. 2021,68,123–131.[CrossRef]

DosSantosMaia,M.;SoaresRodrigues,G.C.;SilvaCavalcanti,A.B.;Scotti,L.;Scotti,M.T.ConsensusAnalysesinMolecular DockingStudiesAppliedtoMedicinalChemistry.Mini-Rev.Med.Chem.2020,20,1322–1340.[CrossRef]

Houston, D.R.; Walkinshaw, M.D. Consensus Docking:Improving the Reliability of Docking in a Virtual Screening Context.J. Chem. Inf. Model. 2013,53,384–390. [CrossRef]

Tsai, K.L.; Yang, L.W. DRDOCK: A Drug Repurposing Platform Integrating Automated Docking, Simulation and a Log-Odds- Based Drug Ranking Scheme. Available online: https://dyn.life.nthu.edu.tw/drdock/(accessed on 24 November 2023).

Eberhardt,J.;Santos-Martins,D.;Tillack,A.F.;Forli,S.AutoDockVina1.2.0:NewDockingMethods,ExpandedForceField,andPython Bindings. J. Chem. Inf. Model. 2021, 61, 3891–3898. [CrossRef] [PubMed]

Trott,O.;Olson,A.J.AutoDockVina:ImprovingtheSpeedandAccuracyofDockingwithaNewScoringFunction,Efficient Optimization, and Multithreading. J.Comput. Chem. 2010, 31, 455–461. [CrossRef] [PubMed]

Rosignoli,S.;Paiardini,A.DockingPie:AConsensusDockingPluginforPyMOL.Bioinformatics2022,38,4233–4234.[CrossRef]

MolecularOperatingEnvironment(MOE);2022.02;ChemicalComputingGroupULC:Montreal,QC,Canada,2023.

Hong,E.;Shin,J.;Kim,H.I.;Lee,S.T.;Lee,W.SolutionStructureandBackboneDynamicsoftheNon-ReceptorProtein-Tyrosine Kinase- 6SrcHomology2Domains. J.Biol.Chem.2004,279,29700–29708. [CrossRef]

Xu, Y.; Wang, S.; Hu, Q.; Gao, S.; Ma, X.; Zhang, W.; Shen, Y.; Chen, F.; Lai, L.; Pei, J. CavityPlus: A Web Server for Protein Cavity DetectionwithPharmacophoreModelling,AllostericSiteIdentificationandCovalentLigandBindingAbilityPrediction.Nucleic AcidsRes. 2018, 46, W374–W379. [CrossRef] [PubMed]

Lee, W.;Ko,S.2KGT:TheSolutionStructureofSH3DomainofPTK6. Availableonline: https://www.rcsb.org/structure/2kgt(accessed on 24 November 2023).

Wilhelm,S.M.; Dumas, J.; Adnane, L.; Lynch, M.; Carter, C.A.; Schütz, G.; Thierauch, K.H.; Zopf, D. Regorafenib (BAY 73-4506):A New Oral Multikinase Inhibitor of Angiogenic, Stromal and Oncogenic Receptor Tyrosine Kinases with Potent Preclinical Antitumor Activity. Int. J.Cancer2011, 129, 245–255. [CrossRef]

Plosker, G.L.; Faulds, D. Epirubicin. A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use inCancer Chemotherapy. Drugs 1993, 45, 788–856. [CrossRef]

Montuschi,P.RoleofLeukotrienesandLeukotrieneModifiersinAsthma.Pharmaceuticals2010,3,1792–1811.[CrossRef]

Lee,C.Daclatasvir:PotentialRoleinHepatitisC.DrugDes.Devel.Ther.2013,7,1223–1233.[CrossRef]

DassaultSystèmesBIOVIA.DiscoveryStudioModelingEnvironment;Release2017;DassaultSystèmes:SanDiego,CA,USA,2016.

Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4:AutomatedDockingwithSelectiveReceptorFlexibility. J.Comput.Chem.2009,30,2785–2791. [CrossRef]

O’Boyle,N.M.;Banck,M.;James,C.A.;Morley,C.;Vandermeersch,T.;Hutchison,G.R.OpenBabel:AnOpenChemicalToolbox. J.Cheminform.2011,3,33.[CrossRef][PubMed]

Corbeil,C.R.;Williams,C.I.;Labute,P.VariabilityinDockingSuccessRatesDuetoDatasetPreparation.J.Comput.AidedMol.Des. 2012,26,775–786.[CrossRef] [PubMed]

Zhou,Y.;Wong,M.W.HalogenBondinginHaspin-HalogenatedTubercidinComplexes:MolecularDynamicsandQuantum Chemical Calculations. Molecules 2022, 27, 706. [CrossRef] [PubMed]

Ang,H.L.;Yuan,Y.;Lai,X.N.;Tan,T.Z.;Wang,L.Z.;Huang,B.B.;Pandey,V.;Huang,R.Y.J.;Lobie,P.E.;Goh,B.C.;etal.Putting theBRKonBreastCancer:FromMolecularTargettoTherapeutics.Theranostics2021,11,1115–1128.[CrossRef]

Downloads

Published

2026-07-09